4,5,6,7-四氢-3-苯基异噁唑[4,5-c]吡啶 | 957480-20-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 4,5,6,7-四氢-3-苯基异噁唑[4,5-c]吡啶
• 英文名称: 3-Phenyl-4,5,6,7-tetrahydroisoxazolo[4,5-c]pyridine
• 英文别名: 3-phenyl-4,5,6,7-tetrahydro-[1,2]oxazolo[4,5-c]pyridine
• CAS: 957480-20-5
• 化学式: C₁₂H₁₂N₂O
• mdl: MFCD07403546
• 分子量: 200.24
• InChiKey: FHEAXPKZNVSNLJ-UHFFFAOYSA-N

物化性质

• 沸点：
  408.9±45.0 °C(Predicted)
• 密度：
  1.153±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  38.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-溴吡唑并[1,5-A]嘧啶-2-羧酸 、 4,5,6,7-四氢-3-苯基异噁唑[4,5-c]吡啶 生成 5-[(6-Bromopyrazolo[1,5-a]pyrimidin-2-yl)carbonyl]-3-phenyl-4,5,6,7-tetrahydroisoxazolo[4,5-c]pyridine
  参考文献：
  名称：

  Substituted pyrazolo[1,5-a]pyrimidines as metabotropic glutamate receptor modulators

  摘要：

  本发明涉及公式（I）的吡唑并嘧啶衍生物，其中：Y1、Y2和Y3独立地为CR10、NH、S或O等；其中至少一个Y1、Y2和Y3代表CR10；R1代表氯或溴；R2、R3、R4、R5、R6和R7代表氢或C1-C6烷基等；R10代表氢、卤素或苯基等；这些衍生物是有效的mGluR5调节剂，例如用于治疗各种神经系统疾病。

  公开号：

  US07947689B2

文献信息

• Pyrazolopyrimidines, a process for their preparation and their use as medicine
  申请人：Danysz Wojciech

  公开号：US20080039476A1

  公开（公告）日：2008-02-14

  The invention relates to pyrazolopyrimidine derivatives of formula (I) wherein Y 1 , Y 2 and Y 3 independently are e.g. CR 10 , NH, S or O, whereby at least one of Y 1 , Y 2 and Y 3 represents CR 10 ; R 1 represents chloro or bromo; R 2 , R 3 , R 4 , R 5 , R 6 and R 7 represent e.g. hydrogen or C 1 -C 6 -alkyl, and R 10 represents e.g. hydrogen, halogen or phenyl; which are potent mGluR5 modulators and are e.g. useful for the treatment of various neurological disorders.

  本发明涉及式(I)的吡唑并嘧啶衍生物，其中Y1、Y2和Y3独立地是例如CR10、NH、S或O，其中至少一个Y1、Y2和Y3代表CR10；R1代表氯或溴；R2、R3、R4、R5、R6和R7代表例如氢或C1-C6烷基，而R10代表例如氢、卤素或苯基。这些化合物是有效的mGluR5调节剂，例如用于治疗各种神经系统疾病。
• QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS
  申请人：Nazaré Marc

  公开号：US20100135999A1

  公开（公告）日：2010-06-03

  The present invention relates to compounds of the formula I, in which R 1 ; R 2 ; R 3 ; R 4 ; R 5 ; R 6 ; Z; A; B; E; X; Q; J; V; G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong anti-aggregating effect on platelets and thus an anti-thrombotic effect and are suitable e.g. for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are reversible antagonists of the platelet ADP receptor P2Y12, and can in general be applied in conditions in which an undesired activation of the platelet ADP receptor P2Y12 is present or for the cure or prevention of which an inhibition of the platelet ADP receptor P2Y12 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

  本发明涉及公式I的化合物，其中R1; R2; R3; R4; R5; R6; Z; A; B; E; X; Q; J; V; G和M具有所述声明中指示的含义。公式I的化合物是有价值的药理活性化合物。它们对血小板具有强烈的抗聚集作用，从而具有抗血栓作用，适用于治疗和预防心血管疾病，如血栓栓塞病或再狭窄。它们是血小板ADP受体P2Y12的可逆拮抗剂，通常适用于存在不良激活血小板ADP受体P2Y12的情况，或者治愈或预防需要抑制血小板ADP受体P2Y12的情况。此外，本发明还涉及制备公式I化合物的方法，它们的用途，特别是作为药物中的活性成分，以及包含它们的制药制剂。
• 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators
  申请人：Merz Pharma GmbH & Co. KGaA

  公开号：EP2090576A1

  公开（公告）日：2009-08-19

  The invention relates to 6-halo-pyrazolo[1,5-a]pyridines of formula (I) as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are mGluR5 modulators and are therefore useful for the control and prevention of acute and/or chronic neurological disorders. wherein A represents -NR3R4 with R3 and R4 as described herein.

  本发明涉及式（I）的6-卤代吡唑并[1,5-a]吡啶以及其药学上可接受的盐。本发明还涉及制备这些化合物的方法。本发明的化合物是mGluR5调节剂，因此对于控制和预防急性和/或慢性神经系统疾病有用。 其中，A表示-NR3R4，其中R3和R4如本文所述。
• PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE
  申请人：Merz Pharma GmbH & Co. KGaA

  公开号：EP2054421A1

  公开（公告）日：2009-05-06
• US7947689B2
  申请人：——

  公开号：US7947689B2

  公开（公告）日：2011-05-24